GlassScriptPhysician profile
Bob K Miyake
NPI 1760590582
$4,860.76
in general payments reported to CMS, 2019-2025
26 companies · $1,756 in 2025
The $1,756 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,853 · 2020: $392 · 2021: $246 · 2022: $23.32 · 2023: $15.27 · 2024: $574 · 2025: $1,756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,098 · Education: $228 · Consulting Fee: $20.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,098.26 |
| Education | $227.52 |
| Consulting Fee | $20.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $925.53 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $784.80 | 2019-2025 | Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $475.97 | 2024-2025 | Dupixent |
| Genzyme Corporation | $375.19 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $263.80 | 2020-2025 | Eohilia, Takhzyro, Cuvitru |
| Csl Behring | $247.32 | 2019-2024 | Haegarda, Hizentra |
| Shire North American Group INC | $217.48 | 2019 | |
| Novartis Pharmaceuticals Corporation | $210.91 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $166.38 | 2024-2025 | Orladeyo |
| Pfizer INC. | $158.71 | 2019-2023 | |
| Grifols USA, LLC | $157.88 | 2019-2025 | Gamunex-C, Prolastin-C Liquid |
| Lilly USA, LLC | $121.55 | 2025 | Ebglyss |
| Pharming Healthcare, INC. | $111.61 | 2019-2024 | Ruconest |
| Octapharma USA, INC. | $104.16 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $78.99 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $75.05 | 2025 | Tezspire |
| Optinose US, INC. | $65.29 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $59.89 | 2019 | |
| Kaleo, INC. | $51.42 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.43 | 2019 | |
| Bio Products Laboratory USA, INC. | $42.69 | 2019-2022 | |
| Genentech USA, INC. | $32.85 | 2025 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $29.03 | 2025 | Neffy |
| Teva Pharmaceuticals USA, INC. | $26.75 | 2019 | |
| Adma Biomanufacturing LLC | $20.33 | 2025 | |
| Cycle Pharmaceuticals INC | $13.75 | 2025 | Sajazir |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bob Miyake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.